drugset / Trial / NCT06730256
A Study of CT0596 in Relapsed/Refractory Multiple Myeloma and Relapsed/ Refractory Plasma Cell Leukemia
Phase 0
Recruiting
24 enrolled
The First Affiliated Hospital of Soochow University
CARsgen Therapeutics Co., Ltd. · collab
NaSingle-groupOpen-labelTreatment
Summary
A Clinical Study to Explore the Safety, Efficacy, and Cellular Metabolic Dynamics of CT0596 CAR-T Cell Injection in Patients With Relapsed/Refractory Multiple Myeloma and Plasma Cell Leukemia.
Timeline
- Start
- 2025-07-23
- Primary completion
- 2027-01-03
- Completion
- 2027-12-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | CT0596 | Cell therapy | — | — |